Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumour promotion response.

Wednesday, 13/10/2010  |   Inflammation  |  no comments

Ferric nitrilotriacetate (Fe-NTA) is a potent nephrotoxicant and a renal carcinogen that induces its effect by causing oxidative stress. The present study was undertaken to explore protective effect of silymarin, a flavonolignan from milk thistle (Silybum marianum), against Fe-NTA mediated renal oxidative stress, inflammation and tumour promotion response along with elucidation of the implicated mechanism(s). Administration of Fe-NTA (10 mg/kg bd wt, i.p.) to Swiss albino mice induced marked oxidative stress in kidney, evident from augmentation in renal metallothionein (MT) expression, depletion of glutathione content and activities of antioxidant and phase II metabolizing enzymes, and enhancement in production of aldehyde products such as 4-hydroxy-2-nonenal. Fe-NTA also significantly activated nuclear factor kappa B (NFkappaB) and up-regulated the expression of downstream genes: cyclooxygenase 2 and inducible nitric oxide synthase and enhancing the production of pro-inflammatory cytokines: tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6). However, feeding of 0.5% and 1% silymarin diet conferred a significant protection against Fe-NTA induced oxidative stress and inflammation. It further augmented MT expression, restored the antioxidant armoury, ameliorated NFkappaB activation and decreased the expression of pro-inflammatory mediators. Silymarin also suppressed Fe-NTA induced hyper-proliferation in kidney, ameliorating renal ornithine decarboxylase activity and DNA synthesis. From these results, it could be concluded that silymarin markedly protects against chemically induced renal cancer and acts plausibly by virtue of its antioxidant, anti-inflammatory and anti-proliferative activities.
Kaur, G., Athar, M., & Alam, M.S. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumour promotion response. Invest New Drugs 2010,Oct,01;28(5) Pp.703-13

Leave a Reply

You must be logged in to post a comment.